Literature DB >> 33625673

Molecular dynamics-guided receptor-dependent 4D-QSAR studies of HDACs inhibitors.

Zhihao Hu1, Qianxia Lin2, Haiyun Liu2, Tiansheng Zhao1, Bowen Yang1, Guogang Tu3.   

Abstract

Histone deacetylases (HDACs) were highlighted as a novel category of anticancer targets. Several HDACs inhibitors were approved for therapeutic use in cancer treatment. Comparatively, receptor-dependent 4D-QSAR, LQTA-QSAR, is a new approach which generates conformational ensemble profiles of compounds by molecular dynamics simulations at binding site of enzyme. This work describes a receptor-dependent 4D-QSAR studies on hydroxamate-based HDACs inhibitors. The 4D-QSAR model was generated by multiple linear regression method of QSARINS. Leave-N-out cross-validation (LNO) and Y-randomization were performed to analysis of the independent test set and to verify the robustness of the model. Best 4D-QSAR model showed the following statistics: R2 = 0.8117, Q2LOO = 0.6881, Q2LNO = 0.6830, R2Pred = 0.884. The results may be used for further virtual screening and design for novel HDACs inhibitors. The receptor dependent 4D-QSAR model was developed for the hydroxamate derivatives as HDAC inhibitors by making use of molecular dynamics simulation to obtain conformational ensemble profile for each compound. The multiple linear regression method was used to generate 4D-QSAR model with the suitable predictive ability and the excellent statistical parameters.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.

Entities:  

Keywords:  4D-QSAR; Hdacs; Molecular dynamics simulations

Mesh:

Substances:

Year:  2021        PMID: 33625673     DOI: 10.1007/s11030-021-10181-y

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  22 in total

Review 1.  Deacetylase enzymes: biological functions and the use of small-molecule inhibitors.

Authors:  Christina M Grozinger; Stuart L Schreiber
Journal:  Chem Biol       Date:  2002-01

2.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

3.  LQTA-QSAR: a new 4D-QSAR methodology.

Authors:  João Paulo A Martins; Euzébio G Barbosa; Kerly F M Pasqualoto; Márcia M C Ferreira
Journal:  J Chem Inf Model       Date:  2009-06       Impact factor: 4.956

Review 4.  Histone deacetylases and cancer: causes and therapies.

Authors:  P Marks; R A Rifkind; V M Richon; R Breslow; T Miller; W K Kelly
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 5.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

6.  Computational ligand-based rational design: Role of conformational sampling and force fields in model development.

Authors:  Jihyun Shim; Alexander D Mackerell
Journal:  Medchemcomm       Date:  2011-05       Impact factor: 3.597

Review 7.  Histone deacetylase as a therapeutic target.

Authors:  O H Krämer; M Göttlicher; T Heinzel
Journal:  Trends Endocrinol Metab       Date:  2001-09       Impact factor: 12.015

Review 8.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

Authors:  Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

9.  A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

Authors:  John L Marshall; Naiyer Rizvi; John Kauh; William Dahut; Manuela Figuera; Min H Kang; William D Figg; Irving Wainer; Christoff Chaissang; Megan Zhaoyang Li; Michael J Hawkins
Journal:  J Exp Ther Oncol       Date:  2002 Nov-Dec

10.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.